Capstone Therapeutics (CAPS) Presents at Rodman & Renshaw Conference

Capstone Therapeutics Corp. (OTC: CAPS) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with underserved medical conditions. Its primary asset is ownership in a joint-venture development company, LipimetiX Development, Inc., based in Natick, Massachusetts.  In 2012, Capstone invested $6 million in the joint venture for 60% ownership. Its partners in the venture include three PhD drug developers, The University of Alabama at Birmingham Research Foundation and scientists at The University of Alabama at Birmingham. For more information, visit the company’s website at www.capstonethx.com.